Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 110

Results For "diseases"

1270 News Found

Kyverna Therapeutics announces licence agreement with NIH
Biotech | January 04, 2022

Kyverna Therapeutics announces licence agreement with NIH

This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel


Expectations and predictions for 2022
Opinion | December 28, 2021

Expectations and predictions for 2022

In India, healthcare has become one of the fastest-growing economic sectors which comprise hospitals, pharma companies, medical equipment and devices, medical tourism, health insurance, clinical trials etc


Healthcare start-up Zorgers raises angel round
Startup | December 27, 2021

Healthcare start-up Zorgers raises angel round

The Home Healthcare market is expected to be US $ 14.2 by 2025


Biocon partner Equillium initiates clinical study for Itolizumab in Lupus Nephritis
Biotech | December 24, 2021

Biocon partner Equillium initiates clinical study for Itolizumab in Lupus Nephritis

Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000


Merck acquires Chord Therapeutics to expand its neuroinflammatory pipeline
News | December 22, 2021

Merck acquires Chord Therapeutics to expand its neuroinflammatory pipeline

Acquisition provides opportunity to develop cladribine in generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD)


Novartis to acquire Gyroscope Therapeutics for up to US $ 1.5 bn
Biotech | December 22, 2021

Novartis to acquire Gyroscope Therapeutics for up to US $ 1.5 bn

Acquisition will add GT005 to the Novartis portfolio, an investigational, one-time gene therapy currently in Phase 2 for the treatment of people living with Geographic atrophy


2022: Predictions for medical and healthcare industry
Opinion | December 20, 2021

2022: Predictions for medical and healthcare industry

2022 is going to be the year of opportunities and innovations from the medical industry in India


Noorik Biopharma signs contract with Switzerland to develop ambrisentan to treat severe Covid-19
Biotech | December 16, 2021

Noorik Biopharma signs contract with Switzerland to develop ambrisentan to treat severe Covid-19

The primary objective of the ongoing trial is to determine whether ambrisentan can prevent the progression to respiratory failure and reduce the need for mechanical ventilation, among others


U.S. FDA approves Bristol Myers Squibb’s Orencia
Drug Approval | December 16, 2021

U.S. FDA approves Bristol Myers Squibb’s Orencia

Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant


Syngene extends contract with Amgen till 2026
News | December 16, 2021

Syngene extends contract with Amgen till 2026

Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects